Genetic/molecular endophenotypes (11.3%, n = 6) explored modifier genes (e.g., GABRG2, SCN1A), polygenic risk scores, and epigenetic markers relevant to epilepsy risk and treatment response. This evidence concerns the gene SCN1A and epilepsy.